Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report
T-cell engager therapies, such as epcoritamab, can play a role in managing patients with refractory DLBCL, including those refractory to CAR T-cell therapy.
Authors
- A. Cheng
- Kai Kammers (ORCID: https://orcid.org/0000-0001-5548-7942)
- Tygh Wyckoff
- Natalie Wallace
- Steven Liu (ORCID: https://orcid.org/0000-0002-0060-6593)
- Jeremy Rosiecki
Institutions
- Providence Alaska Medical Center (US)
- Alaska Oncology & Hematology (US)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1159/000545372
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00